GALT CFO executes 10b5‑1 sales following option exercises
Rhea-AI Filing Summary
Galectin Therapeutics (GALT) reported insider transactions by CFO Jack W. Callicutt. On November 3–4, 2025, he exercised employee stock options at $1.11, $1.72, and $1.98 per share and sold the resulting shares under a pre‑arranged Rule 10b5‑1 plan.
Sales on November 3 were executed at a weighted average price of $6.01 (transactions ranged from $6.00–$6.01). On November 4, sales were executed at a weighted average price of $6.07 (range $6.00–$6.25). Individual lots included 1,300, 1,260, and 1,250 shares on November 3, and 8,914, 8,974, and 10,741 shares on November 4.
Following these transactions, the CFO beneficially owned 7,614 shares directly. The options referenced were from grants with previously disclosed vesting schedules.
Positive
- None.
Negative
- None.
Insights
Pre-set 10b5‑1 sales after option exercises; neutral impact.
The CFO exercised vested employee stock options at strike prices of $1.11, $1.72, and $1.98 and sold the resulting shares on Nov 3–4, 2025. The filing states these transactions were made under a Rule 10b5‑1 plan adopted on Apr 17, 2025.
Reported sales used weighted average prices of $6.01 (range $6.00–$6.01) and $6.07 (range $6.00–$6.25). After the transactions, direct beneficial ownership is 7,614 shares. These mechanics are typical for liquidity and tax management following option exercises.
Because this is a scheduled insider sale without additional corporate developments, it is generally not thesis‑changing. Subsequent filings may provide future activity under the plan.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock option (right to buy) | 8,914 | $0.00 | -- |
| Exercise | Stock option (right to buy) | 8,974 | $0.00 | -- |
| Exercise | Stock option (right to buy) | 10,741 | $0.00 | -- |
| Exercise | Common stock | 8,914 | $1.98 | $18K |
| Sale | Common stock | 8,914 | $6.07 | $54K |
| Exercise | Common stock | 8,974 | $1.11 | $10K |
| Sale | Common stock | 8,974 | $6.07 | $54K |
| Exercise | Common stock | 10,741 | $1.72 | $18K |
| Sale | Common stock | 10,741 | $6.07 | $65K |
| Exercise | Stock option (right to buy) | 1,300 | $0.00 | -- |
| Exercise | Stock option (right to buy) | 1,260 | $0.00 | -- |
| Exercise | Stock option (right to buy) | 1,250 | $0.00 | -- |
| Exercise | Common Stock | 1,300 | $1.98 | $3K |
| Sale | Common Stock | 1,300 | $6.01 | $8K |
| Exercise | Common Stock | 1,260 | $1.11 | $1K |
| Sale | Common Stock | 1,260 | $6.01 | $8K |
| Exercise | Common Stock | 1,250 | $1.72 | $2K |
| Sale | Commno stock | 1,250 | $6.01 | $8K |
Footnotes (1)
- The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025. The shares were sold in multiple transactions at prices ranging from $6.00 to $6.01. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. The options vested as follows: 25% on each of June 30, 2022, December 31, 2022, June 30, 2023, and December 31, 2023. The options vested as follows: 25% on each of June 30, 2023, December 31, 2023, June 30, 2024, and December 31, 2024. The options vested as follows: 25% on each of June 30, 2024, December 31, 2024, and June 30, 2025, with 25% scheduled to vest on December 31, 2025. The shares were sold in multiple transactions at prices ranging from $6.00 to $6.25. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
